Sponsored by
AFX News Limited
10.20.2005, 02:29 AM
BURLINGAME, Calif (AFX) - Genentech Inc said it has entered into a collaboration with Accelerate Brain Cancer Cure (ABC 2), a non-profit foundation, to explore the potential of Avastin for treating patients with glioblastoma multiforme (GBM), an especially deadly form of brain cancer.
The collaboration is focused on a novel imaging study of patients with recurrent GBM who are enrolled in a Phase II clinical trial at Duke University. The two parties will initially share development expenses and if the results are successful, ABC (2) will provide access to its resources for a Genentech-sponsored randomized clinical trial in relapsed GBM.
'Encouraging preliminary data from early-stage research of Avastin in glioblastoma multiforme led us to initiate a Phase II study to gain further insight into Avastin's potential role in this setting,' said Gwen Fyfe, Genentech's vice president of Clinical Hematology/Oncology.
newsdesk@afxnews.com
ak/